- About About
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2021 State of the States Cannabis and Cannabis Resin- Critical Review Preparation Document Medical Cannabis in America
- News News
- Join Join
Policy Recommendations New York
2020-21 Improvements and Recommendations
New York’s legislature legalized cannabis for all adults over 21 by passing A.1248 which was promptly signed by Governor Cuomo in March 2021. While the bill is focused on the retail market, there are some provisions included which should improve functionality for patients by expanding the list of qualified conditions, increasing the number of caregivers each patient may have, placing explicit workplace protections preventing unlawful discrimination from cannabis use, and allowing for patients to grow up to 3 mature cannabis plants at home. The bill also focuses heavily on social justice reforms like automatic criminal records expungement for past cannabis related offenses, as well as a social and economic equity licensing program.
In October 2021, New York’s Department of Labor issued guidance saying that employers cannot drug test most workers for marijuana—going so far as to say the odor of cannabis cannot be used to prove impairment on the job. The Cannabis Control Board of NY voted on Oct. 5th to allow dried flower sales in the state’s medical cannabis dispensaries. They also voted to double every patient’s purchase limit from a 30-day supply to a 60-day supply.
With about 30,000 new registrations in 2020-2021, New York’s medical cannabis registry continued to see steady growth. Unfortunately, the inefficient vertically integrated system of production with high barriers to entry did not grow alongside patient demand. ASA recommends that New York’s legislators remove the rule requiring operators to be vertically integrated and work to expand medical product manfacturing and retail access for medical cannabis patients by licensing new operators to produce both medical and adult use products. The Empire state also has some gaps in its protections of civil rights that need to be covered. Patients must be protected as if they were taking any other medication when it comes to organ transplants and roadside sobriety tests. Patients must also be protected from discrimination in housing as well as in family court and child custody hearings. Finally, New York must take great efforts to improve the product testing and safety standards for their products as the state scored only 27.5% of the points possible in this category.